H. Lundbeck, New data on Ebixa® for mild to moderate Alzheimer’s disease

Preliminary results from two phase III studies investigating Ebixa® (memantine) in the treatment of mild to moderate Alzheimer’s disease were today announced by Forest Laboratories, Inc. and H. Lundbeck A/S respectively.